Lv6
1680 积分 2024-03-06 加入
Recent advances in therapeutic targeting of the KRAS pathway in cancer
24天前
已完结
International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin–exposed High-risk Non–muscle-invasive Bladder Cancer
1个月前
已完结
A SURVEILLANCE SCHEDULE FOR G1Ta BLADDER CANCER ALLOWING EFFICIENT USE OF CHECK CYSTOSCOPY AND SAFE DISCHARGE AT 5 YEARS BASED ON A 25-YEAR PROSPECTIVE DATABASE
1个月前
已完结
European Association of Urology (EAU) Prognostic Factor Risk Groups for Non–muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel
1个月前
已完结
Recent advances in therapeutic targeting of the KRAS pathway in cancer
2个月前
已完结
Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial
2个月前
已完结
Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study
2个月前
已完结
First-Line Therapy For Advanced Non–Clear Cell Renal Cell Carcinoma
3个月前
已完结
Recent advances in therapeutic targeting of the KRAS pathway in cancer
4个月前
已完结
USP1 inhibition: A journey from target discovery to clinical translation
4个月前
已完结
皖公网安备34019202002308
